Preparation of SARS-CoV 3CL protease and synthesis of its inhibitors

被引:0
|
作者
Konno H. [1 ,2 ]
Akaji K. [1 ,2 ]
机构
[1] Graduate School of Science and Engineering, Yamagata University, Yonezawa
[2] Kyoto Pharmaceutical University, Yamashina-ku, Kyoto
关键词
Cysteine protease; Decaisoquinoline; Peptide aldehyde; Phenylisoserine; SARS 3CL protease; Severe acute respiratory syndrome (SARS);
D O I
10.5059/YUKIGOSEIKYOKAISHI.79.2
中图分类号
学科分类号
摘要
Severe acute respiratory syndrome (SARS) is a contagious respiratory disease in humans which is caused by the SARS-CoV. The key enzyme in the processing of polyproteins pp1a and pp1ab, translated by the viral RNA genome of SARS-CoV is called a 3CL protease. Due to its functional importance in the viral life cycle, SARS-CoV 3CL protease is considered to be an attractive target for a drug for SARS therapy. In a research program on SARS 3CL protease, we found for the first time that mature SARS 3CL protease is subject to degradation at the 188Arg/189Gln site, and prepared R188I mutant protease with high activity and stability. Next, practical synthetic routes for the preparation of peptide aldehydes on a solid support were investigated. Efficient transformation of acetal/thioacetal structures as a key step was employed. For the application of the methodology, we designed and synthesized the tetrapeptide aldehyde Ac-Thr-Val-Cha-His-H with an IC 50 value of 98 nM against SARS 3CL protease. In addition, we found new scaffolds, phenylisoserine and decaisoquinoline derivatives connected with the essential functional groups to show the potent inhibitory activities against SARS 3CL protease. © 2021 Society of Synthetic Organic Chemistry. All rights reserved.
引用
收藏
页码:2 / 10
页数:8
相关论文
共 50 条
  • [31] Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
    Su, Haixia
    Yao, Sheng
    Zhao, Wenfeng
    Zhang, Yumin
    Liu, Jia
    Shao, Qiang
    Wang, Qingxing
    Li, Minjun
    Xie, Hang
    Shang, Weijuan
    Ke, Changqiang
    Feng, Lu
    Jiang, Xiangrui
    Shen, Jingshan
    Xiao, Gengfu
    Jiang, Hualiang
    Zhang, Leike
    Ye, Yang
    Xu, Yechun
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [32] Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
    Haixia Su
    Sheng Yao
    Wenfeng Zhao
    Yumin Zhang
    Jia Liu
    Qiang Shao
    Qingxing Wang
    Minjun Li
    Hang Xie
    Weijuan Shang
    Changqiang Ke
    Lu Feng
    Xiangrui Jiang
    Jingshan Shen
    Gengfu Xiao
    Hualiang Jiang
    Leike Zhang
    Yang Ye
    Yechun Xu
    [J]. Nature Communications, 12
  • [33] The Interaction of Antiviral Drugs with SARS-Cov-2 3CL Protease
    Saadh, Mohamed J.
    [J]. JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 (03) : 865 - 868
  • [34] Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
    Niesor, Eric J.
    Boivin, Guy
    Rheaume, Eric
    Shi, Rong
    Lavoie, Veronique
    Goyette, Nathalie
    Picard, Marie-Eve
    Perez, Anne
    Laghrissi-Thode, Fouzia
    Tardif, Jean-Claude
    [J]. ACS OMEGA, 2021, 6 (25): : 16584 - 16591
  • [35] Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
    Zhu, Wei
    Xu, Miao
    Chen, Catherine Z.
    Guo, Hui
    Shen, Min
    Hu, Xin
    Shinn, Paul
    Klumpp-Thomas, Carleen
    Michael, Samuel G.
    Zheng, Wei
    [J]. ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (05) : 1008 - 1016
  • [36] Capillary electrokinetic chromatography for chiral separation of potential SARS-CoV-2 3CL protease inhibitors
    Brier, Lucile
    Furman, Christophe
    Charton, Julie
    Deprez, Benoit
    Lipka, Emmanuelle
    [J]. ELECTROPHORESIS, 2024, 45 (11-12) : 1010 - 1017
  • [37] Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors
    Kumar, Vathan
    Tan, Kian-Pin
    Wang, Ying-Ming
    Lin, Sheng-Wei
    Liang, Po-Huang
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (13) : 3035 - 3042
  • [38] QSAR, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective benzotriazole-based SARS-CoV 3CL protease inhibitors
    D'Souza, Sofia
    Balaji, S.
    Prema, K., V
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (24): : 14247 - 14261
  • [39] Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease
    Konno, Hiroyuki
    Wakabayashi, Masaki
    Takanuma, Daiki
    Saito, Yota
    Akaji, Kenichi
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (06) : 1241 - 1254
  • [40] In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
    Xiong, Muya
    Nie, Tianqing
    Shao, Qiang
    Li, Minjun
    Su, Haixia
    Xu, Yechun
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 231